Found: 59
Select item for more details and to access through your institution.
Retinoic Acid Receptor Alpha Amplifications and Retinoic Acid Sensitivity in Breast Cancers.
- Published in:
- Clinical Breast Cancer, 2013, v. 13, n. 5, p. 401, doi. 10.1016/j.clbc.2013.02.001
- By:
- Publication type:
- Article
Current role of diethylstilbestrol in the management of advanced prostate cancer.
- Published in:
- BJU International, 2012, v. 110, n. 11c, p. E826, doi. 10.1111/j.1464-410X.2012.11206.x
- By:
- Publication type:
- Article
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
- Published in:
- BJU International, 2012, v. 110, n. 11, p. 1747, doi. 10.1111/j.1464-410X.2012.11518.x
- By:
- Publication type:
- Article
Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study.
- Published in:
- Clinical Genitourinary Cancer, 2024, v. 22, n. 2, p. 295, doi. 10.1016/j.clgc.2023.11.012
- By:
- Publication type:
- Article
Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence.
- Published in:
- Clinical Genitourinary Cancer, 2024, v. 22, n. 1, p. 84, doi. 10.1016/j.clgc.2023.11.001
- By:
- Publication type:
- Article
Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG--AFU 26 NIVOREN.
- Published in:
- Clinical Genitourinary Cancer, 2023, v. 21, n. 6, p. 643, doi. 10.1016/j.clgc.2023.07.008
- By:
- Publication type:
- Article
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
- Published in:
- Clinical Genitourinary Cancer, 2022, v. 20, n. 5, p. 488, doi. 10.1016/j.clgc.2022.07.003
- By:
- Publication type:
- Article
Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma.
- Published in:
- Clinical Genitourinary Cancer, 2022, v. 20, n. 1, p. 80, doi. 10.1016/j.clgc.2021.09.001
- By:
- Publication type:
- Article
Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure.
- Published in:
- Clinical Genitourinary Cancer, 2021, v. 19, n. 2, p. 167, doi. 10.1016/j.clgc.2020.10.005
- By:
- Publication type:
- Article
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study.
- Published in:
- Clinical Genitourinary Cancer, 2021, v. 19, n. 1, p. 32, doi. 10.1016/j.clgc.2020.06.003
- By:
- Publication type:
- Article
Testicular ultrasensitive Doppler preliminary experience: a feasibility study.
- Published in:
- Acta Radiologica, 2018, v. 59, n. 3, p. 346, doi. 10.1177/0284185117713350
- By:
- Publication type:
- Article
Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study.
- Published in:
- Supportive Care in Cancer, 2023, v. 31, n. 1, p. 1, doi. 10.1007/s00520-022-07533-1
- By:
- Publication type:
- Article
Feasibility of a video-based cognitive behavioral therapy for insomnia in French adult cancer outpatients: results from the Sleep-4-All-1 study.
- Published in:
- Supportive Care in Cancer, 2021, v. 29, n. 10, p. 5883, doi. 10.1007/s00520-021-06151-7
- By:
- Publication type:
- Article
A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma.
- Published in:
- Oncology Reviews, 2016, v. 10, n. 2, p. 54, doi. 10.4081/oncol.2016.298
- By:
- Publication type:
- Article
Secondary haemophagocytic lymphohistiocytosis is a rare occurrence amongst cancer patients with COVID‐19.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. e87, doi. 10.1111/bjh.17275
- By:
- Publication type:
- Article
Axitinib plus Immuncheckpoint-Inhibitor: evidenz- und expertenbasierte Konsensusempfehlungen für die Behandlungsoptimierung und das Management von therapieassoziierten Nebenwirkungen.
- Published in:
- Kompass Onkologie, 2020, v. 7, n. 4, p. 180, doi. 10.1159/000513091
- By:
- Publication type:
- Article
Langfristige Vollremission mit Ipilimumab bei metastasiertem kastrationsresistentem Prostatakrebs: Fallbericht von zwei Patienten.
- Published in:
- 2018
- By:
- Publication type:
- Other
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
- Published in:
- Drugs, 2022, v. 82, n. 7, p. 719, doi. 10.1007/s40265-022-01703-5
- By:
- Publication type:
- Article
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma.
- Published in:
- Drugs, 2020, v. 80, n. 12, p. 1169, doi. 10.1007/s40265-020-01327-7
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
- Published in:
- Drugs, 2018, v. 78, n. 14, p. 1443, doi. 10.1007/s40265-018-0970-y
- By:
- Publication type:
- Article
Optimal Management of Metastatic Renal Cell Carcinoma: Current Status.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, p. 1, doi. 10.1177/1758835920978134
- By:
- Publication type:
- Article
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920907504
- By:
- Publication type:
- Article
Burned-Out Testis Tumors in Asymptomatic Infertile Men: Multiparametric Sonography and MRI Findings.
- Published in:
- Journal of Ultrasound in Medicine, 2017, v. 36, n. 4, p. 821, doi. 10.7863/ultra.15.08037
- By:
- Publication type:
- Article
Partial nephrectomy versus ablative therapy for the treatment of renal tumors in an imperative setting.
- Published in:
- World Journal of Urology, 2017, v. 35, n. 4, p. 649, doi. 10.1007/s00345-016-1913-4
- By:
- Publication type:
- Article
Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials.
- Published in:
- Oncology Research & Treatment, 2013, v. 36, n. 6, p. 357, doi. 10.1159/000351257
- By:
- Publication type:
- Article
Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience.
- Published in:
- Cancers, 2024, v. 16, n. 5, p. 855, doi. 10.3390/cancers16050855
- By:
- Publication type:
- Article
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves.
- Published in:
- Cancers, 2022, v. 14, n. 16, p. 3931, doi. 10.3390/cancers14163931
- By:
- Publication type:
- Article
Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study.
- Published in:
- Cancers, 2022, v. 14, n. 7, p. 1678, doi. 10.3390/cancers14071678
- By:
- Publication type:
- Article
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.
- Published in:
- Journal of Oncology, 2022, p. 1, doi. 10.1155/2022/3449660
- By:
- Publication type:
- Article
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 3, p. 1116, doi. 10.1007/s10637-011-9671-z
- By:
- Publication type:
- Article
Erratum to: Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.
- Published in:
- 2012
- By:
- Publication type:
- Correction Notice
Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Nivolumab in renal cell carcinoma: latest evidence and clinical potential.
- Published in:
- Therapeutic Advances in Medical Oncology, 2017, v. 9, n. 3, p. 171, doi. 10.1177/1758834016679942
- By:
- Publication type:
- Article
Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma.
- Published in:
- Cancer Cell International, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1475-2867-14-4
- By:
- Publication type:
- Article
Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma.
- Published in:
- Frontiers in Immunology, 2021, v. 11, p. N.PAG, doi. 10.3389/fimmu.2021.670827
- By:
- Publication type:
- Article
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
- Published in:
- Prostate, 2018, v. 78, n. 12, p. 889, doi. 10.1002/pros.23645
- By:
- Publication type:
- Article
Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib.
- Published in:
- BJU International, 2021, v. 128, n. 2, p. 254, doi. 10.1111/bju.15356
- By:
- Publication type:
- Article
Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study.
- Published in:
- BJU International, 2019, v. 123, n. 5, p. 804, doi. 10.1111/bju.14581
- By:
- Publication type:
- Article
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 6, p. 961, doi. 10.1038/s41416-024-02585-y
- By:
- Publication type:
- Article
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Body Composition to Define Prognosis of Cancers Treated by Anti-Angiogenic Drugs.
- Published in:
- Diagnostics (2075-4418), 2023, v. 13, n. 2, p. 205, doi. 10.3390/diagnostics13020205
- By:
- Publication type:
- Article
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
- Published in:
- Acta Oncologica, 2022, v. 61, n. 1, p. 52, doi. 10.1080/0284186X.2021.1995041
- By:
- Publication type:
- Article
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 5, p. 639, doi. 10.1007/s11523-023-00987-1
- By:
- Publication type:
- Article
Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 18, p. 3377, doi. 10.1002/cncr.28218
- By:
- Publication type:
- Article
Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 13, p. 3277, doi. 10.1002/cncr.26666
- By:
- Publication type:
- Article
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.
- Published in:
- Oncologist, 2023, v. 28, n. 6, p. 494, doi. 10.1093/oncolo/oyad028
- By:
- Publication type:
- Article